AstraZeneca bags another US indication for Ultomiris with IgAN approval - Pharmaceutical Technology

Following its provisional blessing in IgAN, AstraZeneca's Ultomiris is now indicated for use in six conditions. Following its provisional blessing in IgAN, Ultomiris is now indicated for use in six conditions. Ultomiris is now approved use in six indications. Credit: Liana Nagieva / Shutterstock.com. AstraZeneca has notched another indication to the belt of its rare disease therapy Ultomiris (ravulizumab) through an accelerated US approval in primary immunoglobulin A nephropathy (IgAN), a type of chronic kidney disease. Following the US Food and Drug Administration’s (FDA) call to initially greenlight Ultomiris in IgAN, the drug will provisionally be available to patients at…

Source: Pharmaceutical Technology